Telomir Pharmaceuticals, Inc. (Nasdaq: TELO), a prominent figure in age-reversal science, disclosed significant findings from a preclinical study focusing on progeria, an uncommon genetic disorder ...

TELO READ THE FULL TELO RESEARCH REPORT Telomir Pharmaceuticals (NASDAQ:TELO) is a preclinical stage biopharmaceutical company developing a product designed to lengthen the DNA’s protective telomere ...

Packing the capabilities of a mid-size truck into a nimble, city-friendly design. This 'unreal' Mini Cooper-size all-electric ...

As EV powertrains unlock new potentials, this startup automaker aims to deliver Tacoma interior and bed space in a much, much ...

Telomir Pharmaceuticals (TELO) announced findings from a preclinical progeria lifespan study conducted in collaboration with Nagi Bioscience ...

Telomir Pharmaceuticals (NASDAQ: TELO) , an emerging leader in age-reversal science, announced significant findings from a preclinical progeria life ...

This financial boost reflects investor confidence in Telo’s strategic plans and growth potential. For further insights into TSE:TELO stock, check out TipRanks’ Stock Analysis page. TipRanks is ...

By Dinasena Rathugamage The People’s Liberation Organisation of Tamil Eelam (PLOTE) and the Tamil Eelam Liberation ...

Telo is a new company, based in San Francisco, that believes it has created ‘urban adventure vehicle with a difference’. Founded by Jason Marks, a specialist in Lidar and autonomous driving, and ...

Telomir Pharmaceuticals, Inc. (NASDAQ:TELO), or the "Company", an emerging leader in age-reversal science, today announced significant findings from its copper binding studies with Telomir-1.

Detailed price information for Telo Genomics Corp (TELO-X) from The Globe and Mail including charting and trades.